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Introduction
Most conventional vaccines are composed of inactivated
pathogens or their subunits, and primarily elicit
humoral immunity. In contrast, it has proved difficult
to induce combined CD4+ and CD8+ T-cell immunity in
humans (1). Dendritic cells (DCs) are antigen-presenting
cells (APCs) specialized to initiate T-cell immunity,
including cytotoxic T lymphocytes (CTLs) that kill virus-
infected or malignant targets (2). DCs normally reside in
tissues in an immature form, where they are specialized
to capture antigen. After antigen capture, and in
response to inflammatory stimuli, DCs switch to a T
cell–stimulatory mode by a process termed maturation
and migrate to lymph nodes to initiate immunity (2).
Maturation of DCs is associated with upregulation of
costimulatory molecules, severalfold enhancement of
their APC function, and expression of chemokine recep-
tors that promote migration to nodal T-cell areas (3).
In several animal studies, immunization with antigen-
bearing DCs efficiently primes both CD4+ helper and
CD8+ cytotoxic T-cell immunity. This leads to protective
immunity against tumors and infectious agents (4–7).
There have been preliminary reports of using immature
DCs in patients with malignancies (8–12). These studies
mostly emphasized the issues of safety and suggested
potential antitumor efficacy. However, it is difficult to
assess the immunogenicity of DCs in these studies
because the CD8+T-cell immunity was not quantified and
because in some of the studies, the patients often also
received soluble antigens, i.e., keyhole limpet hemocyanin
(KLH) or idiotype protein in addition to DCs (8). Evalua-
tion of T-cell immunity was largely based on delayed-type
hypersensitivity (DTH) reactions or in vitro proliferative
responses after multiple DC doses; unpulsed DC controls
were not tested. Additionally, in some studies, DCs were
grown in the presence of FCS, which is known to induce
syngeneic T-cell responses in culture and could have pro-
duced nonspecific immunomodulatory effects in vivo (10,
12). The biology of DCs is sufficiently intricate that their
use as adjuvants will require quantitative T-cell assays to
identify optimal immunization conditions (13).
We have developed a method to reproducibly generate
mature DCs from blood monocyte precursors (14). We
chose these mature DCs for active immunization, as they
are more potent APCs in vitro and do not revert to
macrophages after withdrawal of cytokines, as in the case
of immature DCs used in other studies (14). We targeted
healthy subjects to enable us to study DC biology in vivo
in humans without the confounding variables of tumor-
associated immunodeficiency or comorbidity. Here we use
several parameters of antigen-specific T-cell function,
including newer quantitative assays (15, 16) to show that
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Dendritic cells (DCs) are potent antigen-presenting cells that initiate protective T-cell immunity in
mice. To study the immunogenicity of DCs in humans, we injected 9 healthy subjects subcutaneously
with a control injection of autologous monocyte-derived, mature DCs, followed 4–6 weeks later by
DCs pulsed with keyhole limpet hemocyanin (KLH), HLA-A*0201–positive restricted influenza
matrix peptide (MP), and tetanus toxoid (TT). Four more subjects received these antigens without
DCs. Injection of unpulsed DCs, or antigens alone, failed to immunize. Priming of CD4+ T cells to
KLH was observed in all 9 subjects injected with KLH-pulsed DCs, and boosting of TT-specific T-
cell immunity was seen in 5 of 6 subjects injected with TT-pulsed DCs. Injection of antigen-pulsed
DCs led to a severalfold increase in freshly isolated MP-specific, IFN-γ–secreting CD8+ T cells in all
6 HLA-A*0201–positive subjects, as early as 7 days after injection. When T cells were boosted in cul-
ture, there was an increase in MHC tetramer–binding cells and cytotoxic T cells after DC vaccina-
tion. These data provide the first controlled evidence of the immunogenicity of DCs in humans, and
demonstrate that a single injection of mature DCs rapidly expands T-cell immunity.
J. Clin. Invest. 104:173-180 (1999).
antigen-pulsed mature DCs rapidly generate broad T-cell
immunity in humans. The T-cell responses are evident in
both CD4+ and CD8+ T-cell compartments.
Methods
Study design. The schema for DC injection is shown in
Figure 1. As additional controls, 4 subjects received sub-
cutaneous injections of antigens alone without adjuvants.
Human subjects. Normal healthy adult subjects were
recruited through advertisement. Eligibility criteria were
as follows: age, 18–65 years; no history of chronic infec-
tion (e.g., hepatitis, tuberculosis) or malignancy; and
acceptable hepatic (serum transaminases <3 upper limit
normal), renal (serum creatinine <1.5 upper limit nor-
mal), and hematologic function (hematocrit >30%, gran-
ulocytes >1,500/µL, and platelets >100,000/µL). Indi-
viduals with psychiatric disorders, active substance
abuse, allergy to gentamicin (used in the culture medi-
um), pregnancy, or autoimmune disease (including pos-
itive rheumatoid factor or serum antinuclear antibody
[ANA]) were excluded. The study was approved by the
Food and Drug Administration. All subjects signed an
informed consent in accordance with the Rockefeller
University Institutional Review Board guidelines.
Baseline studies. All study participants were typed for
HLA-A*0201 and were initially followed up for a 2- to
12-month period, during which 2–4 baseline measure-
ments of immune response were made. Laboratory tests
at baseline included complete blood count, chemistry
profile, hepatitis B and C serology, HIV serology,
rheumatoid factor, ANA, sedimentation rate, urinalysis,
chest x-ray, pregnancy test, and influenza serology. An
anergy panel consisting of candida, mumps, and tetanus
was placed at baseline in all but 2 subjects (D4 and D7).
Measurement of immune responses
Antigen-specific proliferation. PBMCs at 2 dose levels (3 ×
104 and 1 × 105 cells per well) were cultured in triplicate
wells in the absence or presence of graded doses of anti-
gens. The antigen and doses were as follows: tetanus tox-
oid (TT) at 3–3,000 ng/mL, KLH at 1–10 µg/mL, and as
a positive control, 0.001–1.0 ng/mL staphylococcal
enterotoxin A (SEA). Assays were pulsed with [3H]thymi-
dine after 3 (SEA) or 5 (TT and KLH) days of culture and
were harvested 8 hours later. For some experiments,
PBMCs were depleted of CD4+ or CD8+ T cells by pan-
ning before use in the proliferation and enzyme-linked
immunospot (ELISPOT) assays.
ELISPOT assay for IFN-γ release from single antigen-specif-
ic T cells. As described elsewhere (16, 17), graded doses of
PBMCs (25 × 103 to 2 × 105 cells per well) were added to
plates precoated with 10 µg/mL of a primary anti–IFN-
γ mAb (Mabtech, Stockholm, Sweden) in the presence
or absence of antigens, to stimulate IFN-γsecretion. The
plates were incubated overnight (12–18 hours) at 37°C,
and then the wells were incubated with biotin-conju-
gated anti–IFN-γ antibody (1 µg/mL; Mabtech). After
staining with Vectastain Elite kit (Vector Laboratories,
Burlingame, California, USA), colored spots indicated
the IFN-γ–secreting cells. Antigens were as follows: 10
µM HLA-A*0201 restricted influenza matrix peptide
(MP) (GILGFVFTL) (18) and 1 µg/mL HLA-A*0201
restricted HIV gag peptide (SLYNTVATL) (as control).
For the detection of influenza-specific responses,
PBMCs were infected with live influenza virus (moi = 2).
Responses were counted as positive if a minimum of 10
spot-forming cells (SFCs) per 2 × 105 cells were detected
after the control had been subtracted, and if the num-
bers of spots were at least twice those in the negative
control wells. All assays were performed on fresh
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ID Age(yrs) Sex HLA-A*0201 Control DCs Antigen-pulsed DCs
status Dose (×106)Purity (% CD83) Local reaction Dose (×106)Purity (% CD83) Antigens Local reaction
D1 30 F (+) 2 19 None 2 53 KLH, MP 20 × 10A
D2 24 F (+) 1.5 45 None 2 66 TT, KLH, MP 20 × 15A
D3 32 F (+) 2 50 None 1.6 75 KLH, MP 2 × 2A
D4 24 M (+) 2 38 None 3.5 43 TT, KLH, MP None
D5 30 F (+) — — — 4 64 TT, KLH, MP 8 × 8A
D6 35 F (+) 2 61 None 1.6 75 TT, KLH, MP 2 × 2A
D7 36 M (–) 2 61 None 4 73 TT, KLH, MP 45 × 35A
D8 23 M (–) 2 95 None 4 93 KLH, MP None
D9 30 F (–) 2 58 None 2.8 42 TT, KLH, MP None
A1 29 M (+) — — — Antigen only — TT, KLH, MP TT:10 × 10A, MP:10 × 8A, KLH: none
A2 61 M (+) — — — Antigen only — TT, KLH, MP TT: none, MP: none, KLH: none
A3 34 M (+) — — — Antigen only — TT, KLH, MP TT:25 × 25A, MP: none, KLH: none
A4 55 M (–) — — — Antigen only — TT, KLH, MP TT: 25 × 25 (erythema and 
induration), MP: none, KLH: none
AErythema (mm). F, female; M, male.
PBMCs. Where feasible, for some subjects, aliquots of
PBMCs from before and after immunization were also
thawed and assayed together.
CTL assays. MP-specific killer cells were quantified after
T-cell stimulation (2 × 105 T cells per well) with antigen-
pulsed DCs (influenza MP [1 µM], live or heat-inactivat-
ed influenza virus [moi = 2]) at a DC/T ratio of 1:30 for 7
days (19, 20). CTL activity was measured in a standard 5-
hour 51Cr-release assay at an effector/target (E/T) ratio of
20:1. For HLA-A*0201–positive patients, targets were T2
cells pulsed with 1 µM MP, or unpulsed T2 cells as con-
trols. In HLA-A*0201–negative patients, autologous B
lymphoblastoid cell lines infected with live influenza (moi
= 10) or vaccinia vectors (moi = 5) carrying influenza
matrix protein or thymidine kinase gene (as control; a gift
of B. Moss, National Institutes of Health, Bethesda, Mary-
land, USA) served as targets.
Binding to HLA class I tetramer complexes. Soluble
influenza MP–HLA-A*0201 tetramers were prepared,
and binding to tetramers was analyzed by FACS® analy-
sis (21). Frozen aliquots of PBMCs from before and after
immunization were thawed together in a blinded fash-
ion. The PBMCs were cultured in vitro with freshly gen-
erated autologous DCs pulsed with MP (versus no pep-
tide as control) at a DC/T ratio of 1:30 for 7 days before
staining and analysis.
Generation of DCs. DCs were generated from blood
monocyte precursors as described (22). Briefly, mononu-
clear cells were plated in 6-well culture plates at 8 × 106
cells per well and allowed to adhere to plastic for 2 hours.
Plastic adherent cells were cultured in RPMI-1640
(BioWhittaker, Walkersville, Maryland, USA) supple-
mented with 1% autologous plasma, 20 µg/mL gentam-
icin (clinical grade; Fujisawa USA, Deerfield, Illinois,
USA), 800 U/mL GMP grade IL-4 (Cell Genix, Freiburg,
Germany), and 100 IU/mL clinical grade GM-CSF
(Immunex, Seattle, Washington, USA) for 7 days. Cultures
were supplemented with cytokines on days 2, 4, and 6. On
day 7, cells were transferred to new plates and cultured in
the presence of 50% (vol/vol) monocyte-conditioned medi-
um (MCM) for 2 additional days. Using this methodolo-
gy, 1.5 × 106 to 4 × 106 mature DCs expressing high levels
of CD86, CD83, and HLA-DR, and lacking other lineage
markers (e.g., CD14), were reproducibly generated from
80mL of peripheral blood. MCM was prepared by adher-
ing 50 × 106 PBMCs in 7 mL of 1% autologous plasma to
plates precoated with 100 µg/mL human IgG (Bayer
Corp., Elkhart, Indiana, USA) for 90 minutes. The PBMCs
were harvested after overnight culture of adherent cells
and were filtered and frozen at –20°C before use. We have
shown previously that mature DCs generated using this
methodology are potent stimulators in mixed lymphocyte
reaction at T/DC ratios of 900:1 (22).
DC injection. The first injection was a control injection
in which no antigen was added. This was followed 4–6
weeks later by the injection of antigen-pulsed DCs. Anti-
gens were added to DCs overnight 1 day before injection.
The antigens were as follows: 10 µg/mL KLH (depyro-
genated, LPS free; Calbiochem-Novabiochem Corp., San
Diego, California, USA), 10 µg/mL TT (Statens Serum
Institute, Copenhagen, Denmark), and 1 µM HLA-
A*0201 restricted influenza MP (manufactured under
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(a) Priming to KLH after KLH-pulsed DCs. KLH-specific proliferation
at baseline and at 30 days after control DC injection and KLH-pulsed
DC injection are shown (except in D5, who demonstrated priming
only at day 60). For A1–A4, data shown are for baseline and 30 days
after antigen injection. For each measurement shown, 105 PBMCs
were incubated with 10 µg/mL KLH for 5 days. Results are expressed
as [3H]TdR incorporation in counts per minute. SEM for all meas-
urements was <20%. (b) Kinetics of KLH priming as determined by
antigen-specific proliferation in a representative subject (D1). For
each assay, 3 × 104 or 1 × 105 PBMCs per well were incubated with 1
or 10 µg/mL KLH for 5 days. Results, as shown for 105 PBMCs per
well, are expressed as [3H]TdR incorporation in counts per minute.
(c) CD4 nature of the KLH proliferative response. KLH-specific pro-
liferation in unseparated PBMCs was compared with that after CD4+
and CD8+ T-cell depletion by panning.
good laboratory practice by A. Houghton, Sloan-Ketter-
ing, New York, New York, USA). On the day of injection
(i.e., day 9 or 10 of culture), the DCs were washed free of
antigen and resuspended in normal saline containing 5%
autologous plasma in two 0.2 mL aliquots. Phenotype
and purity of injected DCs were monitored by the expres-
sion of the DC maturation–associated marker CD83 (23),
by flow cytometry. DCs were injected as a superficial sub-
cutaneous injection in 2 adjacent sites on the upper inner
arm, ∼ 4 inches from the axilla. All injected DC prepara-
tions tested negative for bacterial and fungal contamina-
tion. All subjects were observed overnight at the Rocke-
feller University Hospital.
Antigen-only controls. In 4 control subjects, the study
antigens (TT, KLH, and MP) were injected without DCs
or other adjuvant, at 10 µg/mL in 0.4 mL of normal
saline, as separate subcutaneous injections. These sub-
jects were evaluated at 48 hours (for local reaction) and
at 7 and 30 days after injection for evidence of an
immune response.
Follow-up and monitoring. All subjects were evaluated 24
and 48 hours after each DC injection for the occurrence
of DTH reaction or other early toxicity, and were seen in
the clinic 7 and 30 days after each injection for measure-
ment of immune responses. Subsequent follow-up was
at 1–3 monthly intervals. In subjects who had preinjec-
tion skin tests, these tests were repeated at 30 days after
completion of antigen-pulsed DC injections. Thirty days
after all DC injections, and every 3 months thereafter, all
subjects had a repeat hemogram, serum chemistry panel,
and laboratory tests for rheumatoid factor and ANA.
None of the patients had serologic evidence of intercur-
rent acute influenza infection during the study.
Statistical analysis. For analysis of the immune response,
values before and after immunization were compared by
paired t test after logarithmic transformation of the data.
Generation of a relevant immune response was defined
before the study as ≥2-fold increase in antigen-specific
proliferation for KLH and TT, or the number of IFN-
γ–producing cells in the ELISPOT assay. Significance
was set at P < 0.05.
Results
Clinical characteristics. The clinical characteristics of the
subjects are shown in Table 1. Eight healthy subjects (5
HLA-A*0201–positive and 3 HLA-A*0201–negative)
received an initial control injection of autologous DCs
without antigen, followed a month later by antigen-
pulsed DC injection. In 1 additional subject (D5), the
control injection before antigen-pulsed DCs was omit-
ted. Pulsing of DCs with TT was omitted in 3 subjects
who had significant induration and erythema (>30 mm)
to a baseline TT skin test (D1, D3, D8). Four additional
control subjects (3 HLA-A*0201–positive [A1–A3] and 1
HLA-A*0201–negative [A4]) were injected with antigen
alone in the absence of adjuvant or DCs. The median cell
dose of control DC injection was 2 × 106 cells; for anti-
gen-pulsed DC injection, 2.8 × 106 cells. The percentage
of injected CD83+ cells in the preparations was variable
(range 19–95%), owing to variable T-cell contamination;
however, >85% of the large cells were CD83+.
Toxicities. Injection of the control DCs was well tolerat-
ed, without any local reaction or systemic toxicity (Table
1). A local reaction in the form of erythema without
induration was seen in more than half of the subjects
after antigen-pulsed DC injection. All antigen-pulsed
DC injections were well tolerated, without systemic tox-
icity, with the exception of transient fatigue (D5) and
low-grade fever (D6) on the day of the injection. Among
the 4 subjects injected with antigens alone (without
DCs), 3 developed erythema at the TT site (with indura-
tion in 1 subject), and 1 had a mild local reaction at the
MP injection site, whereas no local reaction was observed
at the KLH site in any of the subjects. None of the study
participants experienced any rash or lymphadenopathy
or developed any clinical evidence of autoimmunity or
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Figure 3
Boosting of TT-specific immunity after TT-pulsed DCs. TT-specific pro-
liferation was measured at baseline and at 30 days after control DC injec-
tion and TT-pulsed DC injection. In D1, D3, and D8, TT was omitted
from the antigen-pulsed DCs because of strong baseline DTH responses.
For A1–A4, data shown are for baseline and 30 days after antigen-only
injection. For each measurement shown, 105 PBMCs were incubated with
3 µg/mL TT for 5 days. Results are expressed as stimulation index. SEM
for all measurements was <20%.
Table 2
DTH reaction to TT: response to immunization
Before immunization After immunization
Erythema (mm) Induration (mm) Erythema (mm) Induration (mm)
D2 2 x 2 None 20 x 20 8 x 8
D5 8 x 8 None 40 x 40 10 x 10
D6 9 x 9 None 28 x 21 17 x 11
D9 7 x 10 5 x 5 22 x 30 10 x 10
rheumatoid disease. One subject developed transient
low-titer (1:40) ANA reactivity at 60 days after immu-
nization, without any other serologic or clinical evidence
of autoimmunity.
Immune responses
CD4+ T-cell responses. There was no priming to KLH, as
assessed by antigen-specific proliferation after injections
of the control DCs or antigen only at either the 7- or 30-
day time point (Figure 2a). In contrast, priming to KLH
was seen in all 9 subjects after injection of antigen-pulsed
DCs (P < 0.001). To illustrate the data, measurements on
a representative subject (D1) are shown (Figure 2b). Prim-
ing to KLH was noted by 30 days after injection in 8 of 9
patients and by day 60 in all patients, but it was evident
as early as 7 days after injection in 2 patients (not shown).
In the 3 patients with longer follow-up, KLH priming was
still detectable at 60–90 days after injection in 2 of 3 sub-
jects. KLH-specific T-cell proliferative responses were
mediated by CD4+T cells, as depletion of CD8+T cells did
not alter the responses (Figure 2c).
Similarly, TT-specific immunity was boosted in 5 of 6
subjects, as assessed by antigen-specific proliferation (P
= 0.001) (Figure 3). No boosting of TT responses was
observed in the 3 subjects (D1, D3, D8) who did not
receive TT-pulsed DCs. Of the 4 subjects who were skin
tested to TT at baseline and 1 month after DC injection,
all 4 (including D6, who failed to show an increase in
proliferative response) demonstrated an enhanced DTH
response to TT (Table 2).
CD8+ T-cell responses in uncultured PBMCs. MP or
influenza-specific IFN-γ–secreting cells were quanti-
fied in fresh PBMCs using an ELISPOT assay. There
was no significant increase in MP or influenza-reac-
tive IFN-γ SFCs, after either the control DC injection
or injection of antigen alone. In contrast, an enhance-
ment of MP-specific T cells after antigen-pulsed DCs
was seen in all 6 A*0201–positive subjects (P < 0.001)
and in none of the 3 A*0201–negative control subjects
(Figure 4a). To illustrate the data, measurements on a
representative subject (D6) are shown (Figure 4b). Five
of 6 subjects had ≥2-fold increase in MP-reactive T
cells (median of 5-fold, corresponding to 100–200
MP-reactive T cells per 106 PBMCs). Increases in
influenza-specific T cells in the ELISPOT assay were
seen in 4 of 6 subjects after immunization (D1, D2,
D3, and D5; data not shown). Most MP-specific SFCs
were CD8+, as reactivity was lost by depletion of CD8+,
but not CD4+, T cells (Figure 4c). When cryopreserved
samples from before and after immunization were
thawed together, similar findings were noted in the
ELISPOT assay, but the number of SFCs was 40–50%
less than in fresh PBMCs (not shown). The respond-
ing ELISPOT-positive cells were capable of respond-
ing to influenza virus as well as to MP. Analysis of
lytic CD8+ cells in fresh bulk PBMCs failed to detect a
significant increase in MP-specific CTLs in any of the
subjects (not shown).
Recall CD8+ T-cell responses in tissue culture. In contrast,
a ≥2-fold increase in MP-specific recall CTLs was seen
in 5 of 6 HLA-A*0201–positive subjects and in none of
the HLA-A*0201–negative control subjects (Figure 5a).
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(a) Boosting of HLA-A*0201 restricted influenza MP-reactive T cells
after MP-pulsed DCs. MP-reactive T cells were quantified using an
ELISPOT assay. HLA-A*0201 restricted gag peptide served as control.
Results are shown as the number of SFCs per 2 × 105 PBMCs, at base-
line and 30 days after the injection of control DCs, MP-pulsed DCs, or
MP alone without DCs. SEM for all measurements was <20 %. (b) Kinet-
ics of boosting of MP-reactive T cells in a representative subject (D6).
MP-reactive T cells were quantified using an ELISPOT assay. HLA-
A*0201 restricted gag peptide served as control. For each assay, grad-
ed doses of PBMCs (25 × 103 to 2 × 105 cells per well) were incubated
with 10 µM influenza MP. Results are shown as the number of SFCs per
2 × 105 PBMCs per well, at various time points. (c) CD8+ nature of the
MP-reactive T cells in the ELISPOT assay. The presence of MP-reactive T
cells in unseparated PBMCs was compared with that after CD4 and CD8
depletion by panning. Data are from subject D1.
In the 2 patients with a longer follow-up, the increased
recall CTL responses to MP were maintained for up to
60–90 days after injection (Figure 5b).
When cryopreserved PBMCs from before and after
immunization were thawed together and cocultured
with MP-pulsed or unpulsed DCs, expansion of MP-spe-
cific T cells, assessed by tetramer binding, was noted in
the available preimmunization samples from only 1 of
the 3 subjects tested, which correlated with the subjects’
preimmunization ELISPOT data (Figure 6). However, in
the samples from after immunization with DCs, a sig-
nificantly higher expansion of MP-specific CD8+ T cells
was detected, with tetramer binding in all 3 samples
assayed at 7 days (D5 and D6; Figure 6) and 90 days (D1;
Figure 7) after immunization.
Discussion
Our study demonstrates that mature DCs are effective
adjuvants in humans, capable of broadly expanding T-cell
immunity — including not only CD4+ T helper cells, but
also CD8+ effector and memory T cells. This is, to our
knowledge, the first report using these DCs, and it pro-
vides the first controlled evidence of the immunogenici-
ty of DCs in humans. Humans respond rapidly to a sin-
gle injection of mature DCs, within a week in many cases,
and within 30 days in all. The generated T-cell responses
after a single injection are durable and last >90 days. In
contrast, injection of the same antigens subcutaneously
without DCs failed to generate or boost immunity. In
studies that were carried out decades ago, injection of
KLH at doses >10 µg was shown to generate T-cell immu-
nity (24). However, the KLH preparations were not well
defined, in particular for LPS contamination. In our
study, when endotoxin-depleted KLH and TT were
administered alone without any adjuvant at doses used
to pulse DCs, the proteins failed to elicit measurable T-
cell immunity, illustrating the value of DCs for both
priming (in the case of KLH) and boosting (in the case of
TT) CD4-positive T-cell responses. We did detect a weak
antibody response to KLH in 3 of 4 subjects injected with
KLH alone (M. Dhodapkar et al., unpublished data), indi-
cating that a humoral, but not a T-cell, response was
elicited in these patients. These data also add to the grow-
ing body of evidence that injection of DCs in humans is
safe and clinically well tolerated.
The ability of DCs to enhance both antigen-specific
CD4+ and CD8+ T-cell responses is important, as both
may be required for protective immunity against
viruses and tumors and for the function of memory
CD8+ T cells (25, 26). Previous approaches for elicit-
ing T-cell responses in humans have included the
injection of class I restricted peptides (e.g., melanoma
peptides) with noncellular adjuvants (27), recombi-
nant viral vectors (e.g., poxviruses) (28), DNA vaccines
(29), or immature DCs (8, 10). However, several injec-
tions have been required to generate detectable immu-
nity. Furthermore, it has been necessary to use 
prolonged culture and repetitive in vitro stimulation
with cytokines and antigen to detect these responses
(28, 29). In direct contrast, we could detect the expan-
sion of antigen-specific CD8+ T cells directly in fresh-
ly isolated T cells. We also showed an increase in T-cell
function when the T cells from DC-immunized indi-
viduals were boosted in short-term (7-day) cultures.
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Figure 5
(a) Boosting of MP-specific CTLs after MP-pulsed DCs. T cells were
cocultured with DCs pulsed with 1 µM MP (unpulsed DCs as con-
trols) for 7 days (DC/T ratio = 30:1), and lytic activity was tested
against appropriate targets as described in Methods (E/T ratio =
20:1). Data shown are from before injection and 30 days after con-
trol DC injection and antigen-pulsed DC injection, and represent per-
cent MP-specific lysis after subtracting the background lysis with
unpulsed DCs. SEM for all measurements was <20%. (b) Enhance-
ment of MP-specific memory CTLs after MP-pulsed DC injection. T
cells were cocultured with DCs pulsed with MP (unpulsed DCs as con-
trols) for 7 days (DC/T ratio = 1:30), and lytic activity was tested
against MP-pulsed or unpulsed T2 targets (E/T ratio = 20:1). Data
shown represent percent MP-specific lysis after subtracting the back-
ground lysis with unpulsed DCs, in 2 representative subjects (D1 and
D3), with longer follow-up. SEM for all measurements was <10%.
Specifically, there was a large increase in cells that
bound MHC tetramers and killed targets. These find-
ings illustrate the potency of DCs in generating T-cell
immunity. A possible explanation for the more rapid,
effective, and broad immunization that we observed
may be our use of mature DCs, which are the most
potent APCs in vitro (22), or maybe the subcutaneous
route of administration, in contrast to other reports
that have used immature DCs administered intra-
venously or intranodally (8, 10). However, direct com-
parison of various maturation stages of DCs and of
DCs with other approaches is needed to evaluate their
relative potency at eliciting T-cell immunity.
A distinguishing feature of our study is the use of a
complement of newer sensitive and quantitative assays
(including ELISPOT and MHC tetramer–binding assay)
to monitor induction of CD8+ T-cell immunity (15, 16).
These assays allow quantification of CD8+ T cells and
their function (IFN-γproduction and cytolytic activity).
The use of DCs as APCs in recall assays enables us to elic-
it information about T-cell memory without the need for
in vitro cytokine stimulation, which is often employed
in assays using other, less potent APCs. Together, the
panel of CD8+ T-cell assays indicates the capacity of DCs
to stimulate effector and recall responses in humans.
KLH and TT were used in our subjects to monitor the
stimulation of CD4+ T cells. These CD4+ T cells may also
have provided help for the generation of CD8+ T-cell
responses, e.g., by “conditioning” DCs (30). Further clin-
ical studies are needed to explore this possibility and to
optimize variables such as DC maturational state, route
of administration, dose, and schedule. Given the fact
that tumors and viruses have several mechanisms to
evade the immune response (25), it should be valuable to
optimize the immune response, so that DCs can best be
tested in the immunotherapy and prevention of viral and
malignant disease in humans (13, 31).
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